INTRODUCTION {#sec1-1}
============

*Helicobacter pylori* (*H. pylori*) is known as a risk factor for gastric cancer. It was classified as a type I carcinogen by the International Agency for Research on Cancer (IARC) in 1994.\[[@ref1]\] Long-term *H. pylori* infection can lead to premalignant histological changes such as atrophic gastritis and intestinal metaplasia.\[[@ref2]\] Although the incidence of gastric cancer has decreased substantially in the Western world, it is still the fourth most common cancer and the second leading cause of mortality due to cancers worldwide.\[[@ref3]\] South Korea has the highest incidence rate of gastric cancer.\[[@ref3]\] Nationwide biennial gastric cancer screening for individuals aged 40 years or older has been conducted in South Korea since 1999.\[[@ref4]\] Recently, there has been an increased concern about early eradication of *H. pylori* to prevent gastric cancer.\[[@ref5]\]*H. pylori* infection is also a risk factor for peptic ulcer diseases (PUD) and gastric MALT lymphoma. The updated American College of Gastroenterology (ACG) guideline strongly recommends *H. pylori* eradication for patients with PUD, a history of PUD, low-grade gastric MALT lymphoma, or a history of endoscopic resection of early gastric cancer.\[[@ref6]\] The success rate of eradication therapy in South Korea has been reported to be around 80% recently.\[[@ref7][@ref8]\] However, a negative result on follow-up test after *H. pylori* treatment does not guarantee subsequent persistent eradication status in the future. To prevent progression of premalignant histological changes and recurrent peptic ulcer diseases, it is important to maintain *H. pylori* eradication status after successful treatment.

After successful eradication, *H. pylori* may be detected again. This is usually considered a recurrence. However, recurrence refers to the recrudescence of the original strain of *H. pylori* that remains suppressed and undetectable, whereas reinfection refers to infection by a new strain of *H. pylori*.\[[@ref9]\] Reported rate of annual recurrence, sometimes including reinfection, ranges from 2.0% to 9.1% in Korean studies.\[[@ref10][@ref11][@ref12][@ref13][@ref14]\] The rate of recurrence generally varies depending on the country, race, research period, research method, and so on. Reviewing recurrence rate can help us assess the relevance of treatment and predict future development of *H. pylori*-related diseases. Due to socioeconomic development and improved hygiene in South Korea, the prevalence of *H. pylori* infection has gradually decreased, although it is still over 50%.\[[@ref15]\] Types of eradication regimens and bacterial resistance may also affect the recurrence rate. Along with these various changes, the recurrence rate of *H. pylori* in South Korea is also changing. The aim of this study was to determine the recurrence rate of *H. pylori* after successful eradication in an endemic area and to identify baseline and clinical factors related to the recurrence.

PATIENTS AND METHODS {#sec1-2}
====================

Study design and patients {#sec2-1}
-------------------------

Consecutive persons who participated in the voluntary health screening program at National Cancer Center, South Korea, between January 2007 and December 2012 were considered. The National Cancer Center has established a screening cohort for health checkups since 2001. Inclusion criteria were: screening cohort participants who provided informed consent screening cohort, those who underwent annual gastric cancer screening with upper endoscopy and *H. pylori* test, and those who were suitable as study subjects based on appropriate physical examination and questionnaire. Among 10,651 persons who met the inclusion criteria, 5,216 case persons had positive *H. pylori* test results during the study period, and 1,755 persons received anti-*H. pylori* treatment. Among them, 1,476 cases for which *H. pylori* eradication was successful were eligible for the study[Figure 1](#F1){ref-type="fig"}. Of them, 531 subjects were excluded as they did not undergo annual follow-up endoscopy after successful eradication. We additionally excluded subjects because of the following reasons: follow-up endoscopy with interval less than 12 months (*n* = 166), those who did not undergo *H. pylori* test on follow-up endoscopy (*n* = 114), and those who were diagnosed with primary or metastatic gastric cancer (*n* = 18). Finally, 647 subjects were included in the analysis. Information relating to patients\' endoscopic findings and their baseline characteristics was obtained via questionnaires and review of medical records. This study was approved by the Institutional Review Board of the National Cancer Center (NCCNCS13739).

![Study flow of screening cohort. We selected 647 subjects who were successfully treated for *H. pylori*](SJG-25-251-g001){#F1}

Endoscopy and *H. pylori* eradication {#sec2-2}
-------------------------------------

All participants underwent esophagogastroduodenoscopy (GIF-H260, Olympus Optical Co., Ltd, Tokyo, Japan) after fasting overnight. Pharyngeal anesthesia with 4% xylocaine spray was routinely performed and intravenous midazolam was administered for conscious sedation. During each endoscopic examination, a rapid urease test (Pronto Dry; Medical Instruments, Solothurn, Switzerland) was routinely performed via a specimen obtained from the greater curvature of the corpus. *H. pylori*-positive subjects, who were clinically indicated for *H. pylori* eradication or according to patients\' desire, received a 7-day triple therapy with omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily as the first-line anti-*H. pylori* treatment. Quadruple regimen was provided as a second line therapy for patients who were considered as having triple therapy failure. Assessment of successful *H. pylori* treatment was performed at least 4--5 weeks after the end of the eradication treatment, using a histological examination, a rapid urease test, or a C^13^urea breath test. Patients were instructed not to take antacids during the period. Those with all negative results from available tests were regarded as successfully eradicated persons. *H. pylori* recurrence was defined when *H. pylori* infection was confirmed in a rapid urease test on follow-up screening endoscopy performed at intervals of 12 months or more after a confirmed successful *H. pylori* eradiation. The period was defined as follow-up interval. For subjects who did not have a recurrence, follow-up interval was calculated as the period from the time of successful eradication to the last follow-up endoscopy within the study period.

Statistical analysis {#sec2-3}
--------------------

Annual recurrence rate of *H. pylori* in the study population was calculated by dividing the total number of re-infected subjects by the total number of patient year observed (%), and Kaplan--Meier survival analysis was performed. Baseline characteristics and clinical findings were compared between subjects with *H. pylori* recurrence ("case group") and those who showed persistently successful eradication status ("control group"). Pearson\'s Chi-square test or Fisher\'s exact test was used to compare categorical variables (sex, regimen of eradication, smoking and drinking status, comorbidity, medication history, and endoscopic findings) whereas independent sample *t*-test or Mann--Whitney U-test was used to compare continuous variables (age, follow-up period, and anthropometric indices). Multivariate logistic regression analyses using odds ratios (ORs) and 95% confidence intervals (CIs) were performed considering significant factors with *P* values less than 0.05 in the univariate analysis and possible confounding factors. All *P* values are two-sided. Statistical significance was considered when *P* value was less than 0.05. SPSS Statistics 19.0 (IBM, Armonk, NY, USA) was used for all statistical analyses.

RESULTS {#sec1-3}
=======

Baseline demographic data {#sec2-4}
-------------------------

The mean age of the study population was 50.9 ± 8.5 years, and 62% were male. Median follow-up interval was 42 months (range: 12-98 months). *H. pylori* recurrence was observed in 21 (3.25%) of 647 enrolled subjects, whereas the remaining 626 subjects showed persistent eradication status. Annual recurrence rate was 0.91% (1.1% in males and 0.59% in females). Kaplan--Meier survival curve was shown in [Figure 2](#F2){ref-type="fig"}. Results of comparison of baseline demographics and clinical findings between patients with *H. pylori* recurrence and those with persistent eradication are shown in [Table 1](#T1){ref-type="table"}. Mean age was significantly higher in *H. pylori* recurrence group than that in the control group (55.9 vs 50.7 years, *P* = 0.006). Median follow-up was significantly lower in *H. pylori* recurrence group (34 months, range: 16--71 months) than that in control group (42.5 months, range: 12--98 months) (*P* = 0.031). Among the study population, 88 (13.6%) subjects received second line therapy. The number of subjects receiving second line therapy was not significantly different between the recurrence group and the control group. There was no significant difference in anthropometric indices, smoking status, drinking status, comorbidity, medication history, or endoscopic findings between the two groups.

![Kaplan--Meier survival curve for *H. pylori* recurrence](SJG-25-251-g002){#F2}

###### 

Characteristics of the study population

  Variables                        Total (*n*=647)   Control group (*n*=626)   Recurrence group (*n*=21)   *P*
  -------------------------------- ----------------- ------------------------- --------------------------- -------
  Age, mean±SD                     50.9±8.5          50.7±8.5                  55.9±8.4                    0.006
  Male sex, *n* (%)                401 (62.0)        385 (61.5)                16 (76.2)                   0.173
  Follow-up (mo), mean±SD          42.7±19.2         43.0±19.3                 33.6±11.9                   0.002
  Second line regimen, *n* (%)     88 (13.6)         86 (13.7)                 2 (9.5)                     0.755
  Height (cm), mean±SD             165.6±8.1         165.5±8.0                 168.1±8.5                   0.139
  Weight (kg), mean±SD             66.6±11.3         66.5±11.2                 70.0±14.1                   0.172
  Current smoking, *n* (%)         169 (26.1)        164 (26.2)                5 (23.8)                    0.806
  Current drinking, *n* (%)        427 (66.0)        412 (65.8)                15 (71.4)                   0.593
  Hypertension, *n* (%)            115 (17.8)        111 (17.7)                4 (19.0)                    0.777
  Diabetes, *n* (%)                38 (5.9)          37 (5.9)                  1 (4.8)                     0.999
  Dyslipidemia, *n* (%)            66 (10.2)         64 (10.2)                 2 (9.5)                     0.999
  Cancer, *n* (%)                  30 (4.6)          28 (4.5)                  2 (9.5)                     0.254
  Heart disease, *n* (%)           31 (4.8)          30 (4.8)                  1 (4.8)                     0.999
  Aspirin, *n* (%)                 59 (9.1)          57 (9.1)                  2 (9.5)                     0.999
  NSAID, *n* (%)                   4 (0.6)           4 (0.6)                   0 (0)                       0.999
  Atrophic gastritis, *n* (%)      264 (40.8)        254 (40.6)                10 (47.6)                   0.518
  Intestinal metaplasia, *n* (%)   83 (12.8)         80 (12.8)                 3 (14.3)                    0.743
  Peptic ulcer, *n* (%)            71 (11.0)         69 (11.0)                 2 (9.5)                     0.999

SD: Standard deviation

Clinical features related to *H. pylori* recurrence {#sec2-5}
---------------------------------------------------

We performed univariate and multivariate logistic regression analyses \[[Table 2](#T2){ref-type="table"}\]. The model included age, sex, follow-up month, type of regimens, smoking status, drinking status, history of cancer, atrophic gastritis and height. Adjusted OR for *H. pylori* recurrence was 1.08 per each increase in age (*P* = 0.012). Follow-up duration was significantly different in univariate analysis. However, it did not show significant difference between the two groups in the multivariate analysis (adjusted OR: 0.98, *P* = 0.085). Other variables showed no significance in multivariate logistic regression analysis either. Next, we performed multivariate regression analysis with age as a categorical variable (\<50, 50--59 and ≥60 years). Adjusted ORs for *H. pylori* recurrence were 0.20 (95% CI: 0.06--0.69) and 0.25 (95% CI: 0.08--0.76) for age group of 50--59 years and age group of less than 50 years (*P* = 0.011 and *P* = 0.014, respectively) compared to age group of ≥60 years.

###### 

Odds ratios for *H. pylori* recurrence in regression model

  Variables            Crude OR   95% CI       *P*     Adjusted OR   95% CI       *P*
  -------------------- ---------- ------------ ------- ------------- ------------ -------
  Age\*                1.07       1.02-1.13    0.006   1.08          1.02-1.14    0.012
  Male sex             2.00       0.72-5.54    0.181   0.98          0.20-4.92    0.981
  Follow-up (mo)\*     0.97       0.95-0.99    0.031   0.98          0.95-1.00    0.085
  Second regimen       0.66       0.15-2.89    0.582   0.53          0.11-2.49    0.418
  Current smoking      0.88       0.32-2.44    0.807   0.89          0.30-2.65    0.830
  Current drinking     1.30       0.50-3.40    0.594   1.19          0.39-3.64    0.762
  Cancer               2.25       0.50-10.13   0.292   2.23          0.43-11.51   0.337
  Atrophic gastritis   1.33       0.56-3.18    0.520   1.20          0.46-3.14    0.710
  Height (cm)\*        1.04       0.99-1.10    0.141   1.06          0.97-1.15    0.213

CI, confidence interval; OR, odds ratio.\*Included as continuous variables

DISCUSSION {#sec1-4}
==========

Some meta-analyses have reported that the global recurrence rate of *H. pylori* is approximately 2.8% to 4.3% per person-year.\[[@ref16][@ref17]\] Our finding showed an annual recurrence rate of 0.91%, which was much lower than results reported in recent Korean studies.\[[@ref11][@ref12][@ref13][@ref18]\] The low recurrence rate of our study could be due to some plausible reasons. It is known that the recurrence rate is high in areas with high prevalence of *H. pylori*.\[[@ref19][@ref20]\] Therefore, our low recurrence could be due to a gradually decreasing trend of *H. pylori* prevalence in Korea recently.\[[@ref15]\] A recent meta-analysis showed that the recurrence rate of *H. pylori* is inversely correlated with national health development index (HDI).\[[@ref16]\] HDI is a composite index measuring average achievement in three basic dimensions of human development: (i) life expectance at birth; (ii) mean and expected years of schooling; and (iii) gross national income per capita.\[[@ref16]\] Therefore, another reason for the low recurrence rate might be associated with an increasing HDI in South Korea. Because recrudescence rather than reinfection is likely to be responsible for most cases of recurrence,\[[@ref20]\] public interest in *H. pylori* eradication and increase in compliance might have contributed to the decreased recurrence rate in South Korea. Lastly, our study targeted a health screening population. This might lead to outcomes different from previous studies that targeted patients who visited outpatient clinics.

As mentioned earlier, chronic *H. pylori* infection can induce premalignant histological changes. Recent researches have highlighted the global burden of noncardiac gastric cancer attributable to chronic *H. pylori* infection.\[[@ref21][@ref22]\] It is known that *H. pylori* treatment can improve gastric histology including mucosal inflammation and atrophic change.\[[@ref23][@ref24]\] Therefore, early treatment of *H. pylori* and persistence of treated condition might be important for the prevention of gastric cancer. In addition, recurrence of peptic ulcers is significantly lower in successfully eradicated patients.\[[@ref25][@ref26]\] In a recent randomized trial, no ulcer recurred in patients who maintained persistent *H. pylori* eradication for one year while the rate of ulcer recurrence after *H. pylori* eradication in ulcer patients was 6.7% to 25.7%.\[[@ref27]\] To maintain *H. pylori* eradicated status, it is necessary to know which patients are more likely to have recurrence. In previous studies, underdeveloped country, male gender, low education level, low income, high number of family members, and the presence of peptic ulcer have been found to be risk factors related to *H. pylori* recurrence.\[[@ref11][@ref28][@ref29][@ref30]\]

The present study found that increasing age was an independent risk factor for *H. pylori* recurrence, consistent with a recent study,\[[@ref31]\] but inconsistent with others.\[[@ref32][@ref33][@ref34]\] There are a few possibilities to consider in terms of the positive association between advanced age and recurrence rate. First, severe atrophic and metaplastic changes due to increasing age can lead to false negative result on follow-up test after *H. pylori* eradication. Frequent use of proton pump inhibitors also can affect the result of *H. pylori* test. In addition, decreasing compliance due to lack of concern in *H. pylori* eradication and increasing resistance of *H. pylori* to eradication according to advanced age might be possible causes. Recurrence rates are known to be high in young children or adults with intellectual disability in some previous studies.\[[@ref35][@ref36][@ref37]\] This may represent the importance of compliance in terms of maintaining successful eradication status. Lastly, elderly people tend to lack the idea of hygiene and maintain traditional eating habits in Korea. They could be vulnerable to *H. pylori* recurrence compared to younger people.

This is a relatively large-scale cohort study performed in an endemic areaof *H. pylori*. Because study subjects were enrolled from a screening cohort of participants who underwent regular follow-up endoscopy and routine urea breath test, results of *H. pylori* tests and follow-up intervals were strongly reliable. Moreover, we identified various clinical conditions including social history, anthropometrics, comorbidity, medication history, and endoscopic findings of cohort subjects. Thus, it could minimize possible confounders. In addition, we performed a follow-up test at least 4--5 weeks after the end of *H. pylori* eradication. Moreover, patients were instructed not to take any antacids during the period from the end of the treatment until the follow-up test of *H. pylori*. This might have increased the accuracy of follow-up tests. Nevertheless, this study had several limitations. First, this was a single-center study of a tertiary cancer center. Therefore, we cannot exclude the possibility of selection bias which could affect *H. pylori* recurrence rate. Multicenter studies to determine whether geographic location is associated with *H. pylori* recurrence rate will help identify the overall recurrence rate of the general population. Second, enrolled subjects voluntarily participated in screening endoscopy. These subjects may have had higher health concerns and better health behaviors or economic status compared to the general population. Third, we did not have data related to self-administration of proton pump inhibitors or antibiotics that could affect *H. pylori* results and underestimate the recurrence rate. Further observations are required to confirm persistent eradication status. Fourth, some patients with recurrence could potentially have had a false negative *H. pylori* test, meaning an eradication failure rather than a recurrence. In addition, patients without recurrence during the study period might be positive in subsequent follow-up, especially in those with short-term intervals. However, because annual follow-up was done and median follow-up period was relatively long, the probability of false negatives can be neglected. Fifth, we routinely performed rapid urease test on screening endoscopy after successful *H. pylori* eradication, some of which may be false negative. However, the sensitivity and specificity of the rapid urease test performed at the greater curvature of the corpus were as high as 96% and 100%, respectively, in our institute.\[[@ref38]\] Finally, recrudescence and reinfection could not be clearly distinguished in our study.

CONCLUSION {#sec1-5}
==========

Annual *H. pylori* recurrence rate is 0.91% in South Korea. Advanced age is at increased risk for *H. pylori* recurrence, and *H. pylori* treatment for patients under 60 years of age was more effective to maintain successful eradication status. In addition, our study implies that additional follow-up tests are required after a confirmation of successful *H. pylori* eradication, especially for elderly patients.
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